Elite Pharmaceuticals Inc (ELTP)

[Couch]

Now let’s look at some of the key areas of our financials. Starting with the P&L statement. Our revenues for the quarter were $2.2 million, approximately $2 million of that came from our generic operations and $250,000 from amortization of the $5 million license fee received from that for SequestOx. That’s a 61% year-on-year increase in revenues. Revenues for the first nine months of the fiscal year from April through December was $7.3 million. That number, that nine month number is almost 50% higher than the $5 million in revenues that we recorded for the entire 12 months of last year. Again this is almost entirely due to the growth in our generic products which continue to perform well as they mature in the market. The financials clear show this growth is being sustained and all data and forecasts that we have give no reason to conclude otherwise when looking forward as well.